A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants

NCT02658825 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: JNJ-63623872 2400 milligram (mg)
DRUG: JNJ-63623872 3000 mg
DRUG: JNJ-63623872
DRUG: Moxifloxacin
DRUG: Placebo (Matching with JNJ-63623872 2400 mg)
DRUG: Placebo (Matching with JNJ-63623872 3000 mg)
DRUG: Placebo (Matching with JNJ-63623872 Dose)
DRUG: Placebo (Matching with Moxifloxacin)

Sponsor

Janssen Research & Development, LLC